Catheter Precision, Inc. (NYSEAMERICAN:VTAK) Short Interest Update

Catheter Precision, Inc. (NYSEAMERICAN:VTAK) saw a large decline in short interest in July. As of July 31st, there was short interest totaling 199,838 shares, a decline of 65.2% from the July 15th total of 574,897 shares. Approximately 5.9% of the company’s shares are short sold. Based on an average trading volume of 5,642,637 shares, the days-to-cover ratio is presently 0.0 days.

Institutional Trading of Catheter Precision

A hedge fund recently bought a new position in Catheter Precision stock. Millennium Management LLC purchased a new position in Catheter Precision, Inc. (NYSEAMERICAN:VTAK) during the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor purchased 34,721 shares of the company’s stock, valued at approximately $64,000. Millennium Management LLC owned approximately 2.08% of Catheter Precision as of its most recent filing with the Securities and Exchange Commission (SEC). 20.34% of the stock is owned by hedge funds and other institutional investors.

Catheter Precision Stock Down 3.4%

Shares of Catheter Precision stock traded down $0.01 during trading on Friday, reaching $0.28. 679,930 shares of the company traded hands, compared to its average volume of 7,092,899. The firm has a market capitalization of $1.01 million, a PE ratio of -0.02 and a beta of -1.00. Catheter Precision has a 1-year low of $0.23 and a 1-year high of $4.31. The company has a 50 day moving average price of $0.67 and a 200-day moving average price of $1.05. The company has a debt-to-equity ratio of 0.35, a current ratio of 0.06 and a quick ratio of 0.06.

Catheter Precision (NYSEAMERICAN:VTAK) last posted its quarterly earnings results on Friday, August 14th. The company reported ($0.92) earnings per share for the quarter, beating the consensus estimate of ($19.00) by $18.08. Catheter Precision had a negative net margin of 1,297.56% and a negative return on equity of 76.51%. The firm had revenue of $1.02 million during the quarter, compared to the consensus estimate of $2.00 million.

Catheter Precision Company Profile

Catheter Precision, Inc (NYSE American: VTAK) is a medical device company specializing in the design, development and manufacture of catheter-based products for interventional cardiology and peripheral vascular procedures. The company’s core business centers on balloon catheter platforms, offering both standard and specialty catheter configurations that address applications ranging from percutaneous transluminal angioplasty (PTA) to percutaneous transluminal coronary angioplasty (PTCA). Catheter Precision’s product portfolio is engineered to meet diverse clinical needs, including high-pressure dilation, scored and cutting balloon therapies, and drug-coated balloon delivery.

All of Catheter Precision’s products are developed in its ISO 13485-certified, FDA-registered manufacturing facility in Bloomington, Minnesota.